Idt Australia Limited · ASX:IDT
Idt Australia — Shareholder Meeting (November 2024)
14 slides from Idt Australia's shareholder meeting presentation, Nov 19, 2024
Slide 1: IDT Australia Annual General Meeting
For personal use only IDT Australia Annual General Meeting November 2024
Slide 2: Disclaimer and Important Notices
Disclaimer and Important Notices This presentation has been prepared by IDT Australia Limited ACN 006 522 970 (Company). It contains general background information only which is current at the date of this presentation unless otherwise specified. It contains selected summary information and does not
Slide 3: FY24 Result Highlights
FY24 Result Highlights Further Achievements in 2nd Year of Strategic Pivot For personal use only Doubling of Revenue in FY24 vs. FY23 '000 $16,000 $14,000 Disbursements/Others Strong Revenue Growth: Operating Revenue doubled to $12.3M $12,000 (+91.1% YoY) and Statutory Revenue +100.8% to $14.1M $10,
Slide 4: Core Pillars
Core Pillars High Growth Opportunities For personal use only Advanced Therapies Active Pharmaceutical Ingredients Specialty Orals 12.5% of Total FY24 Revenue 40.4% of Total FY24 Revenue 39.7% of Total FY24 Revenue TAM $13.1B | SAM $3.4B | SOM $805M1 TAM $250B | SAM $199B | SOM $18M2 TAM $64B | SAM $
Slide 5: Year of Achievements
Year of Achievements Key Milestones Achieved in FY2024 For personal use only Strong start to FY25 with Q1 revenue up 70% pcp IDT Secured Additional Contract with Sanofi Delivers FY24 Revenue Ahead of Guidance Successfully Completes ~$7M Entitlement Offer Secures Key Grant from Victorian Government I
Slide 6: Momentum Carrying Through into FY25
Momentum Carrying Through into FY25 Q1FY25 Further Demonstrates Success in Strategic Transformation For personal use only Total quarterly revenue* jumped 70% pcp to $5.2M – highest since IDT Revenue & Contracts Won in Q1FY25 commenced its strategic transformation program $7 Millions ▪ Advanced Thera
Slide 7: Quarterly Revenue Growth
Quarterly Revenue Growth On Track to Deliver Stronger Full-Year Revenue in FY25 For personal use only Quarterly Revenue: FY25 Revenue Expected to Exceed Prior Year $6 Millions $5 $4 $3 $2 $1 $0 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Quarterly revenue jumped 578% over two year
Slide 8: Levers for Growth
Levers for Growth Drivers of Sustainable Growth to Improve Profitability For personal use only 3 Improving Sales Mix & Repeat Business 2 ▪ Changing sales mix to higher value ADC & mRNA drugs is providing Increasing Utilisation Rates added tailwind for margin expansion. 1 Leveraging the Fixed Cost Ba
Slide 9: Increase in Return Customers
Increase in Return Customers Repeat Business Helped Deliver Solid Q1FY25 Result For personal use only Success of strategic transformation leading to significant increase in returning 37 Proposals* Submitted in Q1FY25 customers – contributing to the strong Q1FY25 result Majority of new proposals subm
Slide 10: Our People & Diversity
Our People & Diversity Increasing Headcount as the Business Scales For personal use only Year-on-Year Headcount Comparison Our people are our greatest asset and we are committed to fostering a diverse, inclusive and highly skilled workforce Team grown to 93 from 38 in early 2021 due to scale-up in m
Slide 11: Key Metrics and Share Price
Key Metrics IDT Australia Share Price: 1 Year* Percentage of Total Shares on Issue For personal use only +42% @ 14 Nov 2024 59.51% Source: Market Index 40.49% Market Cap $53.7M Shares on Issue (#) 429.8M FY24 Revenue $14.1M Cash & Equivalents @ 30 June 2024 $504K^ Top 20 Shareholders Others ^ Does n
Slide 12: Outlook & Summary
Outlook & Summary Drivers in FY25 and Beyond For personal use only 50 Years of Operational Excellence with 30 Novel Chemical Entities Positive Outlook Global Tailwinds Strong momentum into FY25 & growing sales pipeline with Growing demand for mRNA, ADC, mental disorder treatments & further improveme
Slide 13: Glossary Acronym Meanings
Our A D C Antibody Drug Conjugate m R N A Messenger Ribonucleic Acid For personal use only A P I Active Pharmaceutical Ingredient Glossary M D M A Methylene-dioxy-meth-amphetamine A S P Aseptic Sterile Processing O D C Office of Drug Control Acronym c G M P Current Good Manufacturing Practice P T S
Slide 14: IDT Australia
For personal use only IDT Australia Investor & Media Enquiries: Brendon Lau e: brendon@vantagepointpartners.com.au m: 0409 341 613